Pantoprazole
From Wikipedia, the free encyclopedia
 |
|
|
Pantoprazole
|
|
| Systematic (IUPAC) name | |
| (RS)-6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole | |
| Identifiers | |
| CAS number | |
| ATC code | A02 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| Chemical data | |
| Formula | C16H15F2N3O4S |
| Mol. mass | 383.371 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 77% |
| Metabolism | Hepatic (CYP2C19 and 3A4) |
| Half life | 1 hour |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. | |
| Legal status |
℞ Prescription only |
| Routes | Oral and intravenous |
Pantoprazole (Sold as Pantotab; Pantopan; Protium; Protonix; Pantozol; Pantor; Pantoloc; Astropan; Controloc; Pantecta; Inipomp; Somac; Ulcepraz) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary. It can be used as a maintenance therapy for long term use after initial response is obtained. This medication may affect the results of certain lab tests, such as drug screenings (pantoprazole can cause a false positive for THC). It is recommended you make sure laboratory personnel and your doctor know you are using this drug. The active ingredient in PROTONIX (pantoprazole sodium) Delayed-Release Tablets is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion.
Contents |
[edit] Pharmacology
Pantoprazole is metabolized in the liver by the cytochrome P450 system. Metabolism mainly consists of demethylation by CYP2C19 followed by sulfation. Another metabolic pathway is oxidation by CYP3A4. Pantoprazole metabolites are not thought to have any pharmacological significance. Pantoprazole is relatively free of drug interactions, however it may alter the absorption of other medications that depend on the amount of acid in the stomach, such as ketoconazole or digoxin.
[edit] Availability
Pantoprazole was developed by Altana (now owned by Nycomed) and is currently marketed under the brand name Protonix by Wyeth-Ayerst Laboratories, Somac by Pfizer, Astropan by Astron Lifesciences , Pantor by Bosnalijek, and as Pantoloc or Somac by Nycomed, as Protium in the UK, as Inipomp by Sanofi-Aventis or Eupantol by Nycomed in France, as Pantozol by Nycomed in Germany, Propozol in India, Zurcazol in Greece, as Protonex by Abdi İbrahim in Turkey , as Pantup in Ireland and as TopZole in South Africa. It is manufactured by a joint venture company Zydus Altana Private Limited which was formed by Altana and Cadila Healthcare. The plant is located at Thane, Maharashtra 421305, India. It is available by prescription in delayed-release tablets. It is also available for intravenous use.
On December 24, 2007, Teva Pharmaceutical released an AB-rated generic alternative to Protonix.[1]
A study published in the August 12, 2008 issue of the Canadian Medical Association Journal found that those who use proton pump inhibitors for five or more years have a 1.6-fold increased risk of fracturing a hip, while those who use the drugs for 7 or more years have a 4.5 fold increased risk of fracturing a hip. [2][3]
[edit] External links
- Official Protonix Homepage
- Protonix (Pantoprazole Sodium) label
- PubDrug
- Use of proton pump inhibitors and risk of osteoporosis-related fractures Canadian Medical Association Journal, Aug 2008; 179: 319 - 326
- Sharon Kirkey. Antacids could lead to broken bones, study suggests.
[edit] References
- ^ Teva Announces Launch Of Generic Protonix Tablets
- ^ Sharon Kirkey. Antacids could lead to broken bones, study suggests., Canwest News Service August 12, 2008
- ^ Laura E. Targownik, MD MSHS, Lisa M. Lix, PhD, Colleen J. Metge, PhD, Heather J. Prior, MSc, Stella Leung, MSc and William D. Leslie MD. Use of proton pump inhibitors and risk of osteoporosis-related fractures Canadian Medical Association Journal, Aug 2008; 179: 319 - 326
|
||||||||||||||
